Peficitinib - Astellas Pharma
Alternative Names: ASP-015K; ASP-015K hydrobromide; JNJ-54781532; Peficitinib hydrobromide - Astellas Pharma; SmyrafLatest Information Update: 05 Nov 2023
At a glance
- Originator Astellas Pharma
- Class Adamantanes; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; Janus kinase 3 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Rheumatoid arthritis
- Discontinued Plaque psoriasis; Transplant rejection; Ulcerative colitis
Most Recent Events
- 13 Sep 2023 Menarini Asia Pacific in-licenses Peficitinib from Astellas Pharma for Rheumatoid arthritis in Taiwan
- 13 Sep 2023 Astellas Pharma has patent protection for composition of matter for patent named 'Heterocyclic janus kinase 3 inhibitors' before September 2023
- 31 Aug 2022 Preregistration for Rheumatoid arthritis in China (PO) (Astellas Pharma pipeline, November 2022)